Peer-reviewed veterinary case report
Stem cell treatment tested for dogs with spinal cord injury
By Vikartovska, Zuzana et al.·Published in International journal of molecular sciences·2020·University of Veterinary Medicine and Pharmacy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Stem Cell Conditioned Medium Treatment for Canine Spinal Cord Injury: Pilot Feasibility Study.
- Species:
- dog
Plain-English summary
Four dogs with chronic spinal cord injuries, lasting over six months, were treated with a special stem cell therapy called conditioned medium derived from canine bone marrow. Each dog received four intravenous infusions of this treatment over a month, along with ongoing physiotherapy for three additional months. After treatment, all dogs showed clinical improvement in their movement and joint motion, and two of them had better bladder function. There were no side effects noted during the study, suggesting that this treatment could be a promising option for dogs with spinal cord injuries when combined with physical therapy.
People also search for: dog spinal cord injury treatment · canine stem cell therapy · dog physiotherapy for mobility · improving dog bladder function · chronic spinal injury in dogs
Abstract
Spinal cord injury (SCI) involves nerve damage and often leads to motor, sensory and autonomic dysfunctions. In the present study, we have designed a clinical protocol to assess the feasibility of systemic delivery of allogenic canine bone marrow tissue-derived mesenchymal stem cell conditioned medium (BMMSC CM) to dogs with SCI. Four client-owned dogs with chronic SCI lasting more than six months underwent neurological and clinical evaluation, MRI imaging and blood tests before being enrolled in this study. All dogs received four intravenous infusions with canine allogenic BMMSC CM within one month. Between the infusions the dogs received comprehensive physiotherapy, which continued for three additional months. No adverse effects or complications were observed during the one, three and six months follow-up periods. Neither blood chemistry panel nor hematology profile showed any significant changes. All dogs were clinically improved as assessed using Olby locomotor scales after one, three and six months of BMMSC CM treatment. Furthermore, goniometric measurements revealed partial improvement in the range of joint motion. Bladder function improved in two disabled dogs. We conclude that multiple delivery of allogenic cell-derived conditioned medium to dogs with chronic SCI is feasible, and it might be clinically beneficial in combination with physiotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32698543/